Opinions

Gaps still exist in care and communication for AYA, with failure to address their unique needs

Advances in molecular profiling and a greater understanding of the underlying biology are reinforcing the concept of a distinct disease from other ER-positive breast cancers 

COMPASS trial suggests that selecting treatment based on subtypes classification may impact patients’ outcomes, but the approach is hard to implement in clinical practice

Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context

Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC

Recent data provide further evidence that non-risk-based screening can improve survival if biomarkers can be identified to target screening to those at the highest risk

Combining the optimisation of clinical pathways with tumour molecular insights enables more accurate and personalised cancer care

Development of therapies modulating two or more targets is increasing rapidly despite facing a number of hurdles

Semi-autonomous and autonomous foundation models are helping cancer research and anticancer drug development

Recent studies have improved current understanding of clinical variability and molecular diversity of this subgroup, but many questions remain